Mylan A Tough Contender In The Biosimilar Anti-Diabetes Race

Mylan A Tough Contender In The Biosimilar Anti-Diabetes Race

Mylan is going head-to-head with other pharmaceutical giants like Eli Lilly and Merck in competing to launch a biosimilar of Sanofi\'s drug Lantus, which is expected to go off-patent by early 2015

By Aliya Kaleem on Aug 29, 2014 at 7:34 am EST

Mylan A Tough Contender In The Biosimilar Anti-Diabetes Race
comments powered by Disqus